RCUS
Arcus Biosciences, Inc.
NYSE · USHealthcareBiotechnology
$28.17+2.92%
Price as of Jul 20, 2026
RCUS financials
Arcus Biosciences, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $247.0M | $258.0M | $117.0M | $112.0M |
| Cost of revenue | $10.0M | $0.00 | $0.00 | $0.00 |
| Gross profit | $237.0M | $258.0M | $117.0M | $112.0M |
| Operating expenses | $623.0M | $588.0M | $457.0M | $392.0M |
| Operating income | -$386.0M | -$330.0M | -$340.0M | -$280.0M |
| Net income | -$353.0M | -$283.0M | -$307.0M | -$267.0M |
| EBITDA | -$335.0M | -$269.0M | -$291.0M | -$258.0M |
| Basic EPS | $-3.29 | $-3.14 | $-4.15 | $-3.71 |
| Diluted EPS | $-3.29 | $-3.14 | $-4.15 | $-3.71 |
| Balance sheet | ||||
| Cash & equivalents | $222.0M | $150.0M | $127.0M | $206.0M |
| Total assets | $1.1B | $1.1B | $1.1B | $1.3B |
| Total liabilities | $508.0M | $665.0M | $633.0M | $688.0M |
| Stockholders’ equity | $631.0M | $485.0M | $462.0M | $657.0M |
| Total debt | $112.0M | $60.0M | $11.0M | $120.0M |
| Net debt | -$110.0M | -$90.0M | -$116.0M | -$86.0M |
| Cash flow | ||||
| Operating cash flow | -$482.0M | -$170.0M | -$306.0M | $438.0M |
| Capital expenditure | -$2.0M | -$6.0M | -$24.0M | -$6.0M |
| Free cash flow | -$484.0M | -$176.0M | -$330.0M | $432.0M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |